Sign In
Buy ADAP
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
Adaptimmune Announces Changes to Board and Executive Leadership Team
07:30am, Monday, 17'th Nov 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
06:30am, Tuesday, 21'st Oct 2025
WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.
Adaptimmune Announces Delisting from Nasdaq
07:40am, Monday, 20'th Oct 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Compa
Adaptimmune Reports Q2 Financial Results and Provides Business Update
07:30am, Wednesday, 13'th Aug 2025
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to
Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
01:59pm, Tuesday, 13'th May 2025
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Ci
Adaptimmune Reports Q1 Financial Results and Provides Business Update
07:30am, Tuesday, 13'th May 2025
TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$4
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
12:00pm, Wednesday, 07'th May 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
12:10pm, Thursday, 20'th Mar 2025
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Of
Adaptimmune Provides Q4 and Full Year 2024 Business Update
07:00am, Thursday, 20'th Mar 2025
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA sub
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
04:54pm, Wednesday, 12'th Mar 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with c
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
04:00pm, Thursday, 30'th Jan 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor can
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be fe
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
07:30am, Thursday, 19'th Dec 2024
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
04:00pm, Monday, 02'nd Dec 2024
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - Dece
